Belite Bio Inc ADR (BLTE NASDAQ) stock market data APIs
$139.4291
3.15(2.3%)
as of June 8, 2026
Try our APIs with
free plan!
Belite Bio Inc ADR Financial Data Overview
Price chart is built with
Anychart
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Prev. Close
139.4291
Open
142.5802
High
144.0802
Low
137.2118
52 wk Range
56.1-200
Market Cap
5 632 M
Shares Outstanding
40 085 K
EPS
-0.68
Beta
-1.243
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Belite Bio Inc ADR data using free add-ons & libraries
Get Belite Bio Inc ADR Fundamental Data
Belite Bio Inc ADR Fundamental data includes:
- Net Revenue:
- EBITDA: -101 187 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: -0.6429
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Belite Bio Inc ADR News
New
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Belite Bio, Inc SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing n...
Belite Bio Enters Oversold Territory (BLTE)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a te...
Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses
This article first appeared on GuruFocus. R&D Expenses: $15.7 million in Q1 2026, up from $9.4 million in Q1 2025. Non-GAAP R&D Expenses: $13.8 million in Q1 2026, compared to $7.4 million in Q1 2025...
Belite Bio targets completing stargardt NDA rolling submission in Q2 2026 while planning a 30-40 member U.S. launch team
Earnings Call Insights: Belite Bio (BLTE) Q1 2026 MANAGEMENT VIEW * “We have received our Phase III clinical study report in Q1, and without delay in April, we initiated our NDA rolling submissi...
Get Belite Bio Inc ADR fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
